Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination chemotherapy regimen** composed of three cytotoxic drugs: **gemcitabine**, **fluorouracil (5-fluorouracil, 5FU)**, and **docetaxel**. - **Gemcitabine** is a nucleoside analog (specifically a deoxycytidine analog) that inhibits DNA synthesis by incorporation into DNA, resulting in masked chain termination and apoptosis of rapidly dividing tumor cells. - **Fluorouracil** is a pyrimidine analog antimetabolite; it inhibits thymidylate synthase, interfering with DNA synthesis and function. - **Docetaxel** is a taxane antineoplastic that promotes and stabilizes microtubule assembly, preventing cell division and leading to apoptosis. This combination has been studied primarily in the adjuvant treatment of pancreatic and biliary cancers, especially after surgical resection and in combination with chemoradiation, and its feasibility and tolerability have been demonstrated in phase II studies[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gemcitabine + fluorouracil + docetaxel.